These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 7987844)
21. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Andrews PA; Murphy MP; Howell SB Cancer Chemother Pharmacol; 1987; 19(2):149-54. PubMed ID: 3568272 [TBL] [Abstract][Full Text] [Related]
22. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143 [TBL] [Abstract][Full Text] [Related]
23. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Andrews PA; Albright KD Cancer Res; 1992 Apr; 52(7):1895-901. PubMed ID: 1551118 [TBL] [Abstract][Full Text] [Related]
24. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458 [TBL] [Abstract][Full Text] [Related]
25. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Kido Y; Khokhar AR; al-Baker S; Siddik ZH Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629 [TBL] [Abstract][Full Text] [Related]
26. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Okuda T; Lin X; Trang J; Howell SB Mol Pharmacol; 2005 Jun; 67(6):1852-60. PubMed ID: 15758147 [TBL] [Abstract][Full Text] [Related]
27. Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Lin X; Okuda T; Trang J; Howell SB Mol Pharmacol; 2006 May; 69(5):1748-54. PubMed ID: 16495473 [TBL] [Abstract][Full Text] [Related]
28. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes]. Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984 [TBL] [Abstract][Full Text] [Related]
29. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines. Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539 [TBL] [Abstract][Full Text] [Related]
30. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Waud WR Cancer Res; 1987 Dec; 47(24 Pt 1):6549-55. PubMed ID: 3677093 [TBL] [Abstract][Full Text] [Related]
31. Collateral resistance or sensitivity of human larynx carcinoma HEp2 cells resistant to cis-dichlorodiammineplatinum (II) or vincristine sulfate. Osmak M Neoplasma; 1992; 39(3):197-202. PubMed ID: 1528326 [TBL] [Abstract][Full Text] [Related]
32. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
33. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells. Hirama M; Isonishi S; Yasuda M; Ishikawa H Oncol Rep; 2006 Nov; 16(5):997-1002. PubMed ID: 17016583 [TBL] [Abstract][Full Text] [Related]
34. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971 [TBL] [Abstract][Full Text] [Related]
35. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Andrews PA; Murphy MP; Howell SB Cancer Res; 1985 Dec; 45(12 Pt 1):6250-3. PubMed ID: 4063975 [TBL] [Abstract][Full Text] [Related]
36. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Shen D; Pastan I; Gottesman MM Cancer Res; 1998 Jan; 58(2):268-75. PubMed ID: 9443404 [TBL] [Abstract][Full Text] [Related]
37. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line. McLaughlin K; Stephens I; McMahon N; Brown R Cancer Res; 1991 Apr; 51(8):2242-5. PubMed ID: 1901242 [TBL] [Abstract][Full Text] [Related]
38. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Deng HB; Adikari M; Parekh HK; Simpkins H Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708 [TBL] [Abstract][Full Text] [Related]
39. Isolation and characterization of a cisplatin-resistant strain of Schizosaccharomyces pombe. Perego P; Jimenez G; Howell SB Mol Pharmacol; 1996 Nov; 50(5):1080-6. PubMed ID: 8913338 [TBL] [Abstract][Full Text] [Related]
40. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin. Chen G; Zeller WJ Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]